Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission.

Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission.

Item

http://www.wikidata.org/entity/Q33405002

Q33405002

about

Modulation of APC Function and Anti-Tumor Immunity by Anti-Cancer Drugs Customized targeted therapy in Hodgkin lymphoma: hype or hope?Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program.Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin.Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!Evolution of androgen receptor targeted therapy for advanced prostate cancer.Brentuximab vedotin for treating Hodgkin's lymphoma: an analysis of pharmacology and clinical efficacy.Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era.Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma.Strategies to accelerate immune recovery after allogeneic hematopoietic stem cell transplantation.Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors.Cancer chemotherapy agents target intratumoral dendritic cells to potentiate antitumor immunity.18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma.Hodgkin lymphoma, allogeneic transplant and the graft-versus-tumor effect: size does matter.Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation.Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma.

P2860

Q26781522-2E31A600-31D8-4E6E-912C-9A854833CC19 Q27002554-8163FB4A-5FA0-4C4D-98B1-3B299E97C205 Q33420273-28B67231-9738-414B-9CFB-3BE0AF19B882 Q33886267-B5F653B4-4FF1-48E7-8F6C-C3D35C6085D6 Q36833808-F735D095-9295-40F1-ADEE-F0F471B5F32A Q37216260-00DA97F0-861D-456A-BB39-134001C3A6D7 Q37412853-5962474B-FB4F-4FA5-AC52-5001CD1F0771 Q38179975-BBBEFCBD-8C00-4A39-805F-096F79009947 Q38212716-304D7437-B385-462A-A169-8C62F5C8D227 Q38340900-C8B29E41-66A0-4CCF-9A53-B50FBA2D0120 Q38361620-0A16AE08-C21E-4F49-B30F-B68A25D23483 Q38368587-B40E963A-7544-41EF-B18D-C6D8274EAAC9 Q38640239-D4DA60A2-BBFA-4361-A5DC-1481DCDD1D61 Q38664909-0004FE89-E67C-4C0E-99C9-346B85FAD5C0 Q39208496-5894D24C-E3C4-4082-9958-716BA6D4744A Q41545176-B2DE30AC-E837-4438-8877-9859B6EE7621 Q44750052-33059FCF-FAA8-4C6A-B0B7-01A5B4AC24F6 Q45032304-DB6F15B8-F602-4A87-A12B-1360034E00F5 Q45794725-B35EF880-37BF-42B5-BE46-675678E02E6A Q51769462-9AA47FF6-CE35-455E-8C3C-8FDA64160501 Q53315058-17181A86-F47C-49AB-9DF7-6D59C1AD01DB

P2860

Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission.

Item

http://www.wikidata.org/entity/Q33405002

description

2012 nî lūn-bûn

@nan

2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu